Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.

Lee CP, de Jonge MJ, O'Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J.

Clin Cancer Res. 2006 May 1;12(9):2841-8.

3.

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. Epub 2006 Mar 10.

PMID:
16528532
4.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.

5.

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK.

J Clin Oncol. 2001 Jul 1;19(13):3267-79.

PMID:
11432895
6.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.

Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652.

8.
9.

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.

Cancer. 2006 Sep 15;107(6):1383-90.

10.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.

Invest New Drugs. 2006 Jul;24(4):327-33.

PMID:
16502355
11.

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.

Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK.

Clin Cancer Res. 2006 Sep 1;12(17):5207-15.

12.
13.

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK.

J Clin Oncol. 2000 Dec 15;18(24):4086-97.

PMID:
11118470
14.

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2157-66.

15.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.

Ann Oncol. 1995 Feb;6(2):133-40.

PMID:
7786821
16.

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.

Beutel G, Glen H, Schöffski P, Chick J, Gill S, Cassidy J, Twelves C.

Clin Cancer Res. 2005 Aug 1;11(15):5487-95.

17.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2003 Nov 15;9(15):5540-9.

18.

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.

Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML.

Clin Cancer Res. 2008 Dec 1;14(23):7947-55. doi: 10.1158/1078-0432.CCR-08-0864.

19.

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.

Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA.

Clin Cancer Res. 2005 May 1;11(9):3410-6.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk